NGM · Biotechnology

CHRS (CHRS) Stock

$1.42 +3.65% NGM: CHRS Healthcare

Valuation

MetricValue
Price$1.42
Market Cap$219.39M
P/E Ratio-2.21
P/B Ratio3.55
P/S Ratio3.97
EPS (TTM)$0.00
52-Week High$2.62
52-Week Low$0.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-278.69%
ROA-31.20%
ROCE-295.08%
Gross Margin-428.57%
Operating Margin-428.57%
Net Margin-323.49%
Debt/Equity0.69
Current Ratio1.46

Annual Financials (USD)

Metric20212022202320242025
Revenue$327.0M$211.0M$257.0M$267.0M$42.0M
Operating Profit$-264.0M$-257.0M$-203.0M$-112.0M$-180.0M
Net Profit$-287.0M$-292.0M$-238.0M$29.0M$-170.0M
EPS$-3.81$-3.76$-2.53$0.25$-1.45
Op Margin-80.8%-121.7%-79.0%-41.8%-425.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$679.0M$481.0M$630.0M$449.0M$258.0M
Total Liabilities$582.0M$618.0M$823.0M$581.0M$197.0M
Cash$417.0M$64.0M$103.0M$126.0M$89.0M
Borrowings$419.0M$480.0M$481.0M$270.0M$40.0M

Latest News

Coherus Enters Trial Collaboration, Supply Agreement With Zumutor Biologics MT Newswires · Jun 23, 2026 Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) GlobeNewswire · Jun 23, 2026 Sona Nanotech Appoints Seasoned Biotech Commercial Executive Michael A. Fleming to Board of Directors CNW Group · Jun 11, 2026 What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade Today Simply Wall St. · May 14, 2026 Coherus Oncology, Inc. Q1 2026 Earnings Call Summary Moby · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-37.0M$-241.0M$-175.0M$-20.0M$-139.0M
Investing Cash Flow$-140.0M$-169.0M$144.0M$230.0M$375.0M
Financing Cash Flow$54.0M$-2.0M$-5.0M$35.0M$-49.0M
Net Cash Flow$-124.0M$-354.0M$39.0M$23.0M$-37.0M
Free Cash Flow$-39.0M$-243.0M$-175.0M$-20.0M$-139.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-91.67%
Quick Ratio1.52
Interest Coverage-20.00
Return 1Y52.63%
Return 3Y-64.29%
Return 5Y-88.96%

Ownership

Insiders Held18.66%
Institutions Held38.65%
Institutions Float Held47.52%
Institutional HolderSharesReport Date
Blackrock Inc.10,365,0742026-03-31
Vanguard Capital Management LLC5,452,7622026-03-31
Samsara BioCapital, LLC3,428,5712026-03-31
Geode Capital Management, LLC3,121,5782026-03-31
Kohlberg Kravis Roberts & Co. L.P.3,036,0762026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVTX $19.34 +2.06% -2.79 $1.02B 0.00%
CCCC $3.79 -2.07% -2.54 $419.05M 0.00%
CDXS $1.48 -2.32% -5.06 $158.65M 0.00%
IMDX $4.01 +4.43% -2.83 $129.48M 0.00%
IVVD $0.80 -8.63% -3.53 $236.86M 0.00%

About CHRS

CHRS is led by CEO Dennis Lanfear, employs 228 people, headquartered in US, publicly traded since 2014.

CHRS stock trades at $1.42 with a market capitalization of $219.39M. The stock is valued at a price-to-earnings (P/E) ratio of -2.21, price-to-book of 3.55, price-to-sales of 3.97. Over the past 52 weeks the stock has ranged between $0.72 and $2.62, and currently trades 45.7% below its 52-week high.

On profitability, CHRS generates a return on equity (ROE) of -278.69%, return on capital employed of -295.08%, an operating margin of -428.57%, a net profit margin of -323.49%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1160.06 +0.01% JNJ Drug Manufacturers - General $275.21 +1.48% ABBV Drug Manufacturers - General $261.70 +0.66% MRK Drug Manufacturers - General $151.64 +1.19% UNH Medical - Healthcare Plans $399.66 +0.85% NVS Drug Manufacturers - General $162.46 +0.75% AZN Drug Manufacturers - General $161.63 -0.52% AMGN Drug Manufacturers - General $442.84 +1.08% TMO Medical - Diagnostics & Research $608.54 +1.34% NVO Biotechnology $46.77 +3.66% ABT Medical - Devices $110.49 +1.43% GILD Drug Manufacturers - General $149.61 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides